Galderma S.A.
http://www.galderma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Galderma S.A.
J&J Interested In ‘Differentiated’ Obesity Assets
“It would be an area of interest to us,” Johnson & Johnson CEO Joaquin Duato said of the obesity space during the Morgan Stanley Healthcare Conference.
Finance Watch: Zenas, Bicara, MBX Aim To Raise $100m Or More In Future IPOs
Fifteen biopharma firms have launched IPOs in the US this year, but three more have joined the queue. Also, Galderma sold CHF500m ($590.7m) in bonds to pay down debt, Noetik raised a $40m series A round and ImCheck collected €20.18m ($22.4m) from the French government.
Asia Deal Watch: Ocumension Obtains Chinese Rights To Eight Alcon Products
Also deals involving WuXi/Medigene, Eisai/Seed, Genor/Two River/Third Rock Ventures, ImmuneOnco/Instil, Biocytogen/Ideaya, Takeda/Dr Reddy’s/Zydus/Mankind and deals in brief.
Galderma Gets First Biologic To Market With Nemluvio Approval
Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
- Other Names / Subsidiaries
-
- Alastin Skincare, Inc.
- CollaGenex Pharmaceuticals, Inc., Nestle S.A.
- Nestle Skin Health S.A.
- Spirig Pharma AG
- Q-Med AB
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice